CYP2D1 Cancer Research Results

CYP2D1, CYP2D1: Click to Expand ⟱
Source:
Type:
CYP2D1 is a member of the cytochrome P450 enzyme family, but it is less well characterized in human cancer contexts compared to some of its counterparts (such as CYP2D6).
Scientific Papers found: Click to Expand⟱
2216- SK,    Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes
- in-vivo, Nor, NA
*NRF2↑, Shikonin effectively upregulates the transcription of CYP isozymes, phase II detoxification enzymes, and phase III membrane transporters and this function is at least partially through activation of AhR and Nrf2
*AhR↑,
*CYP1A1↑, shikonin dose-dependently increased the protein expression of CYP1A1, CYP1A2, CYP2C6, CYP2D1, and CYP3A2.
*CYP1A2↑,
*CYP2C6↑,
*CYP2D1↑,
*CYP3A2↑,
*NQO1↑, Compared with the controls, cells treated with 2 uM shikonin had 5.5-, 3.0-, and 2.0-fold higher UGT1A1, NQO1, and PGST protein levels


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

CYP1A1↑, 1,   NQO1↑, 1,   NRF2↑, 1,  

Core Metabolism/Glycolysis ⓘ

CYP2C6↑, 1,   CYP3A2↑, 1,  

Cell Death ⓘ

AhR↑, 1,  

Migration ⓘ

CYP2D1↑, 1,  

Drug Metabolism & Resistance ⓘ

CYP1A2↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: CYP2D1, CYP2D1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1268  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page